Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Clinical programs for inhaled insulin have received several setbacks ... Its Technosphere is rapid acting in part because it delivers insulin in monomer form—unlike traditional insulin that ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Exubera, a rapid-acting insulin in powder form ... are also under investigation. In humans, inhaled regular insulin is more rapidly absorbed than insulin from the subcutaneous injection site.

Slight structural modifications in Lispro result in less self-association and more rapid therapeutic ... of monomeric insulin as a means for improving the bioavailability of inhaled insulin.

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Inhaled insulin is a new option for type 2 diabetic patients with poor glycemic control on oral monotherapy. A rapid-acting inhaled insulin (Exubera) was approved recently for treatment of type 1 ...

MESA, AZ (AZFamily) — Inhaled insulin is now considered “standard of care” for diabetics, according to updated guidelines from the American Diabetes Association. Inhaled insulin works faster ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.